What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?

被引:31
作者
Alobaid, Abdulaziz S. [1 ]
Brinkmann, Alexander [2 ,3 ]
Frey, Otto R. [2 ,3 ]
Roehr, Anka C. [2 ,3 ]
Luque, Sonia [4 ,5 ]
Grau, Santiago [4 ,5 ]
Wong, Gloria [1 ]
Abdul-Aziz, Mohd-Hafiz [1 ]
Roberts, Michael S. [6 ]
Lipman, Jeffrey [1 ,7 ,8 ]
Roberts, Jason A. [1 ,7 ,9 ]
机构
[1] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
[2] Gen Hosp Heidenheim, Dept Pharm, Heidenheim, Germany
[3] Gen Hosp Heidenheim, Dept Anaesthesia & Intens Care Med, Heidenheim, Germany
[4] Hosp del Mar, Dept Pharm, Inst Municipal Invest Biomed, Parc Salut Mar, Barcelona, Spain
[5] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
[6] Queen Elizabeth Hosp, Basil Hetzel Inst Translat Hlth Res, Therapeut Res Ctr, Adelaide, SA, Australia
[7] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[8] Queensland Univ Technol, Fac Hlth, Brisbane, Qld 4001, Australia
[9] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
STEADY-STATE PHARMACOKINETICS; BETA-LACTAM ANTIBIOTICS; DOSE OPTIMIZATION; PHARMACODYNAMICS; TAZOBACTAM; OVERWEIGHT; INFUSION;
D O I
10.1093/jac/dkv412
中图分类号
R51 [传染病];
学科分类号
100201 [内科学];
摘要
The objectives of this study were to determine the effects of obesity on unbound trough concentrations and on the achievement of pharmacokinetic (PK)/pharmacodynamic (PD) targets of piperacillin and meropenem in critically ill patients. This study retrospectively analysed therapeutic-drug-monitoring data from ICU databases in Australia, Germany and Spain, as well as from a large PK study. The presence of obesity was defined as a BMI a parts per thousand yen30 kg/m(2), and patients were also categorized based on level of renal function. The presence of obesity was compared with unbound piperacillin and meropenem trough concentrations. We also used logistic regression to describe factors associated with the achievement of the PK/PD targets, an unbound concentration maintained above the MIC breakpoint (100% fT(> MIC) and 100% fT(> 4xMIC)) of Pseudomonas aeruginosa. In all, 1400 patients were eligible for inclusion in the study. The median age and weight were 67 years (IQR 52-76 years) and 79 kg (69-90 kg), respectively, and 65% of participants were male. Significantly lower median piperacillin trough concentrations [29.4 mg/L (IQR 17.0-58.0 mg/L)] were found in obese patients compared with non-obese patients [42.0 mg/L (21.5-73.5 mg/L)] (PaEuroS=aEuroS0.001). There was no difference for meropenem trough concentrations [obese 10.3 mg/L (IQR 4.8-16.0 mg/L) versus non-obese 11.0 mg/L (4.3-18.5 mg/L); PaEuroS=aEuroS0.296]. Using logistic regression, we found that the presence of obesity was not associated with achievement of 100% fT(> MIC), but the use of prolonged infusion, a creatinine clearance a parts per thousand currency sign100 mL/min, increasing age and female gender were for various PK/PD targets for both piperacillin and meropenem (PaEuroS < aEuroS0.05). This large dataset has shown that the presence of obesity in critically ill patients may affect piperacillin, but not meropenem, unbound trough concentrations.
引用
收藏
页码:696 / 702
页数:7
相关论文
共 29 条
[1]
Lower short- and long-term mortality associated with overweight and obesity in a large cohort study of adult intensive care unit patients [J].
Abhyankar, Swapna ;
Leishear, Kira ;
Callaghan, Fiona M. ;
Demner-Fushman, Dina ;
McDonald, Clement J. .
CRITICAL CARE, 2012, 16 (06)
[2]
Pharmacokinetic changes in critical illness [J].
Boucher, Bradley A. ;
Wood, G. Christopher ;
Swanson, Joseph M. .
CRITICAL CARE CLINICS, 2006, 22 (02) :255-+
[3]
Steady-State Pharmacokinetics and Pharmacodynamics of Meropenem in Morbidly Obese Patients Hospitalized in an Intensive Care Unit [J].
Cheatham, S. Christian ;
Fleming, Megan R. ;
Healy, Daniel P. ;
Chung, Eun Kyoung ;
Shea, Katherine M. ;
Humphrey, Melissa L. ;
Kays, Michael B. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (03) :324-330
[4]
Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients [J].
Cheatham, S. Christian ;
Fleming, Megan R. ;
Healy, Daniel P. ;
Chung, Christina E. K. ;
Shea, Katherine M. ;
Humphrey, Melissa L. ;
Kays, Michael B. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 41 (01) :52-56
[5]
PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[6]
Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[7]
Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients [J].
De Waele, Jan J. ;
Lipman, J. ;
Akova, M. ;
Bassetti, M. ;
Dimopoulos, G. ;
Kaukonen, M. ;
Koulenti, D. ;
Martin, C. ;
Montravers, P. ;
Rello, J. ;
Rhodes, A. ;
Udy, A. A. ;
Starr, T. ;
Wallis, S. C. ;
Roberts, J. A. .
INTENSIVE CARE MEDICINE, 2014, 40 (09) :1340-1351
[8]
Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial [J].
De Waele, Jan J. ;
Carrette, S. ;
Carlier, M. ;
Stove, V. ;
Boelens, J. ;
Claeys, G. ;
Leroux-Roels, I. ;
Hoste, E. ;
Depuydt, P. ;
Decruyenaere, J. ;
Verstraete, A. G. .
INTENSIVE CARE MEDICINE, 2014, 40 (03) :380-387
[9]
Optimization of Antibiotic Therapy in the Obese, Critically Ill Patient [J].
Hites, M. ;
Taccone, F. S. .
REANIMATION, 2015, 24 (03) :278-294
[10]
Broad-spectrum β-lactams in obese non-critically ill patients [J].
Hites, M. ;
Taccone, F. S. ;
Wolff, F. ;
Maillart, E. ;
Beumier, M. ;
Surin, R. ;
Cotton, F. ;
Jacobs, F. .
NUTRITION & DIABETES, 2014, 4 :e119-e119